Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening

Journal of Clinical Oncology

Volumn 33, Issue 18, 2015, Pages 2062-2071

  Menon, Usha ^a   Ryan, Andy ^a   Kalsi, Jatinderpal ^a   Gentry Maharaj, Aleksandra ^a   Dawnay, Anne ^b   Habib, Mariam ^a   Apostolidou, Sophia ^a   Singh, Naveena ^c   Benjamin, Elizabeth ^a   Burnell, Matthew ^a   Davies, Susan ^a   Sharma, Aarti ^g   Gunu, Richard ^a   Godfrey, Keith ⁱ   Lopes, Alberto ^j   Oram, David ^d   Herod, Jonathan ^k   Williamson, Karin ^l   Seif, Mourad W ^m   Jenkins, Howard ⁿ   Mould, Tim ^b   Woolas, Robert ^o   Murdoch, John B ^p   Dobbs, Stephen ^q   Amso, Nazar N ^h   Leeson, Simon ^r   Cruickshank, Derek ^s   Scott, Ian ⁿ   Fallowfield, Lesley ^t   Widschwendter, Martin ^a   Reynolds, Karina ^d   McGuire, Alistair ^e   Campbell, Stuart ^f   Parmar, Mahesh ^a   Skates, Steven J ^u   Jacobs, Ian ^a,v   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^f Create Health Clinic   (United Kingdom)

^g UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^j ROYAL CORNWALL HOSPITAL   (United Kingdom)

^k LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^l NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^m ST MARY S HOSPITAL   (United Kingdom)

ⁿ ROYAL DERBY HOSPITAL   (United Kingdom)

^o QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^p ST MICHAEL'S HOSPITAL   (United Kingdom)

^q BELFAST CITY HOSPITAL   (United Kingdom)

^r Llandudno LL30 1LB   (United Kingdom)

^s JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^t UNIVERSITY OF SUSSEX   (United Kingdom)

^u MASSACHUSETTS GENERAL HOSPITAL   (United States)

^v UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; TUMOR MARKER;

ADULT; ALGORITHM; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CLINICAL ASSESSMENT; CONSERVATIVE TREATMENT; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEASUREMENT; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; TUMOR INVASION; UNITED KINGDOM; AGED; BLOOD; EARLY DIAGNOSIS; FOLLOW UP; MASS SCREENING; MIDDLE AGED; OVARY TUMOR; PROCEDURES; QUESTIONNAIRE; RISK FACTOR; TREATMENT OUTCOME;

AGED; ALGORITHMS; BIOMARKERS, TUMOR; CA-125 ANTIGEN; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84930654984     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.4945     Document Type: Article

References (28)

1. Xu JL, Commins J, Partridge E, et al: Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer. Gynecol Oncol 125:70-74, 2012
2. van den Bergh RC, Roemeling S, Roobol MJ, et al: Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer: A review. Eur Urol 54:505-516, 2008
3. Loeb S, Carter HB: Point: Impact of prostate-specific antigen velocity on management decisions and recommendations. J Natl Compr Canc Netw 11:281-285, 2013
4. Vickers AJ: Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer. J Natl Compr Canc Netw 11:286-290, 2013
5. Pinsky PF, Zhu C, Skates SJ, et al: Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Int J Cancer 132:2127-2133, 2013
6. Drescher CW, Shah C, Thorpe J, et al: Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol 31:387-392, 2013
7. Buys SS, Partridge E, Black A, et al: Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305:2295-2303, 2011
8. Menon U, Gentry-Maharaj A, Ryan A, et al: Recruitment to multicentre trials: Lessons from UKCTOCS - Descriptive study. BMJ 337:a2079, 2008
9. Menon U, Gentry-Maharaj A, Hallett R, et al: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10:327-340, 2009
10. Skates SJ, Pauler DK, Jacobs IJ: Screening based on the risk of cancer calculation from Bayesian hierarchical changepoint and mixture models of longitudinal markers. J Am Stat Assoc 96:429-439, 2001
11. Health and Social Care Information Centre: Hospital Episode Statistics. http://www.hscic.gov.uk/hes
12. Kurman RJ, Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 34:433-443, 2010
13. Prat J: Staging classifications for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124:1-5, 2014
14. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44:837-845, 1988
15. Seidman JD, Zhao P, Yemelyanova A: "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: Assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 120:470-473, 2011
16. Partridge E, Kreimer AR, Greenlee RT, et al: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 113:775-782, 2009
17. Kobayashi H, Yamada Y, Sado T, et al: A randomized study of screening for ovarian cancer: A multicenter study in Japan. Int J Gynecol Cancer 18:414-420, 2008
18. Güth U, Huang DJ, Bauer G, et al: Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer 110:1272-1280, 2007
19. Brown PO, Palmer C: The preclinical natural history of serous ovarian cancer: Defining the target for early detection. PLoS Med 6:e1000114, 2009
20. Montagnana M, Danese E, Giudici S, et al: HE4 in ovarian cancer: From discovery to clinical application. Adv Clin Chem 55:1-20, 2011
21. Urban N, Thorpe JD, Bergan LA, et al: Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst 103:1630-1634, 2011
22. Cramer DW, Bast RC Jr, Berg CD, et al: Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 4:365-374, 2011
23. Zhu CS, Pinsky PF, Cramer DW, et al: A framework for evaluating biomarkers for early detection: Validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) 4:375-383, 2011
24. Fleischer AC, Lyshchik A, Hirari M, et al: Early detection of ovarian cancer with conventional and contrast-enhanced transvaginal sonography: Recent advances and potential improvements. J Oncol doi: 10.1155/2012/302858[epub on April 26, 2012]
25. Lu KH, Skates S, Hernandez MA, et al: A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119:3454-3461, 2013
26. Menon U, Skates SJ, Lewis S, et al: Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23:7919-7926, 2005
27. Manchanda R, Abdelraheim A, Johnson M, et al: Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG 118:814-824, 2011
28. Burnell M, Gentry-Maharaj A, Ryan A, et al: Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. Trials 12:61, 2011